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Enophthalmos Is Not Present 
in Horner Syndrome
Robert Daroff
The case report by Nautiyal et al. [1] is an instructive 
reminder that the ﬁ  rst episode of an acute painful Horner 
Syndrome should prompt imaging of the ipsilateral internal 
carotid artery, since carotid dissection (as well as other 
conditions, such as high-grade stenosis) needs to be ruled 
out. Unfortunately, the authors perpetuate the extremely 
common misconception that enophthalmos accompanies 
ptosis and miosis in human Horner Syndrome. It is only an 
illusion of enophthalmos caused by the ptosis. This is evident 
in the left eye of their patient in Figure 1 of the case report.
Actual measurement with exophthalmometry clearly 
demonstrates the lack of enophthalmos. As stated by 
Loewenfeld ([2], p. 1139), “Animals such as cats, rats, or 
dogs have enophthalmos on the side of the sympathetic 
lesion. But in man, the enophthalmos is only apparent. The 
small palpebral ﬁ  ssure makes the eye look sunken in on 
the affected side, but the position of the globe in the orbit 
remains virtually unchanged. This has been found by all 
workers who have measured the supposed enophthalmos 
objectively.” Loewenfeld cites four supportive references.
Thompson and Miller ([3], p. 964) provide four additional 
references that the enophthalmos “is apparent rather than 
real.”  
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Is American Bioethics Lost 
in the Woods?
Michael Cook
The debate between a libertarian bioethicist and a 
communitarian bioethicist [1] illustrates why American 
bioethics is becoming increasingly marginalised and 
irrelevant to the democratic society that it intends to serve. 
Both participants in the debate, Arthur Caplan and Carl 
Elliott, explicitly reject the notion of “human nature” as a 
foundation for bioethics. But without human nature, on what 
grounds can advances in biomedical knowledge be called 
good or bad, right or wrong, or even harmful or beneﬁ  cial? 
Clearly Caplan and Elliott have to accept something as a 
touchstone of their bioethical discourse, or it will lapse into 
windy incoherence. Although they approach it from different 
angles, this benchmark is informed consent, with Elliott 
placing the stress on “informed” and Caplan on “consent”. 
As a result, their lively disagreement over enhancement 
technology is just verbal sparring and not a battle of ideas. 
Caplan believes that the consumer-patient is sufﬁ  ciently 
mature to weigh up the dangers; Elliott is more sceptical. 
Neither appears to think that it makes any sense to argue that 
technology should be suited to human nature. This belief 
seems to be widespread in the bioethics community. Ruth 
Macklin, a bioethicist at Albert Einstein College of Medicine, 
argued recently, for instance, that “human dignity” is an 
empty and meaningless concept [2]. 
However, academic discourse has failed to dislodge from 
the heads of the hoi polloi the conviction that the starting 
point of ethics is not consent but happiness. The man in the 
street, the ultimate consumer of bioethics, still believes in 
human nature. The notion that human dignity is meaningless 
would be regarded by nearly all Americans as not merely 
absurd but reprehensible. 
What I ﬁ  nd odd in the writings of many bioethicists is that 
they skirt around the question that the average person wants 
to ask: will this enhancement make me happy in a deeply 
satisfying and fulﬁ  lling way? He or she is much less interested 
in whether all the boxes on the informed consent form have 
been ticked properly. 
Consequently, as the Caplan–Elliott bunﬁ  ght demonstrates, 
bioethicists are now reduced to arguing that human 
enhancement is good if people want it—even if they want 
it mainly because powerful commercial interests have 
persuaded them to, even if it is weird and kinky, even if it 
won’t make them happy. Elliott’s fascinating book Better than 
Well [3] is evidence that exercising a right to enhancement 
still leaves many lives hollow and unhappy. Sooner or later 
people will ask why they hadn’t been warned, and a lot of 
bioethicists will be looking for jobs.  
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Developing an HIV Vaccine: The Role of 
Efﬁ  cacy Studies in Nonhuman Primates
Klaus Überla
Given the scientiﬁ  c hurdles encountered in HIV/AIDS vaccine 
development, a global effort is needed, and the scientiﬁ  c 
strategic plan proposed by the Global HIV/AIDS Vaccine 
Enterprise [1] is a milestone. The plan also provides an 
important starting point for continued discussion. 
Since only a limited number of HIV/AIDS vaccines can be 
tested for efﬁ  cacy in phase-III studies, evidence-based criteria 
for selection of candidate HIV/AIDS vaccines for these trials 
have to be deﬁ  ned. If an immune correlate of protection 
were available, small-scale immunogenicity studies in humans 
would provide required parameters. However, the speciﬁ  c 
immune responses needed for a successful HIV/AIDS vaccine 
remain unknown. The Global HIV/AIDS Vaccine Enterprise 
prioritizes research on vaccines eliciting neutralizing antibodies 
and T cell responses [1]. Standardization of laboratory assays 
measuring these parameters is proposed to allow comparison 
of different vaccines. 
The main reasons to assume that T cell responses and 
neutralizing antibodies are important for HIV/AIDS vaccine 
efﬁ  cacy are the following: (i) T cell responses and neutralizing 
antibodies are known to have a role in preventing infection 
or disease by other viruses, (ii) there is an inverse correlation 
of T cell responses with viral load in patients with HIV, (iii) 
depletion of CD8+ T cells in nonhuman primate models of 
AIDS increases viral load, and (iv) passive immunization can 
provide protection in some of the nonhuman primate models 
[2]. However, extensive studies during the last 15 years using 
various T cell assays have failed to provide an accepted immune 
correlate of protection in nonhuman primates. Although 
more sophisticated assays and larger groups of animals might 
reveal such a correlate, protection could also be mediated by a 
mechanism not yet deﬁ  ned and therefore not monitored. 
While the Vaccine Enterprise proposes to search for 
correlates of immune protection in nonhuman primate 
models of AIDS, efﬁ  cacy studies in these models are not 
mentioned [1]. The limitations of these models have been 
extensively discussed [3], and there is no proof that these 
models predict efﬁ  cacy in humans. However, if one accepts 
that nonhuman primate models are valid for determination 
of immune correlates of protection, it seems reasonable to 
also assume that a more effective vaccine approach in an 
appropriate nonhuman primate model would also be more 
effective in humans. Thus, by comparing efﬁ  cacies of different 
vaccines in these models, it should be possible to select the 
most promising vaccine approaches for clinical evaluation. 
In the past, the nonhuman primate models have been little 
informative with respect to relative vaccine efﬁ  cacy: the results 
from different laboratories were difﬁ  cult to compare because 
of differences in, among other things, the monkey species, the 
inoculation route and dose, the pathogenicity of the challenge 
virus, the homology between vaccine and challenge virus, and 
the read-out assays used. This problem was recognized almost 
ten years ago already, but no agreement has yet been reached 
on which models most closely resemble HIV transmission and 
infection in humans. Different aspects of vaccine research 
require different animal models. In addition, worldwide use 
of one or two selected models would lead to a shortage in 
the monkey species needed for these models. Therefore, it 
is unlikely that an agreement can be reached at all. Rather 
than going through great and costly efforts to standardize the 
animal models and laboratory assays, a standardized “state of 
the art” vaccine approach could be included as a control group 
in each study. The immunogenicity and efﬁ  cacy of all novel 
vaccine candidates could then be determined relative to the 
immunogenicity and efﬁ  cacy of the vaccine standard.
A number of issues would need to be discussed with respect 
to a generally acceptable vaccine standard. Ideally, results 
from a human efﬁ  cacy study with the standardized vaccine 
approach should be available in near future. The standardized 
vaccine approach should be based on one of the most 
promising vaccines available at present. Due to the diversity 
of immunodeﬁ  ciency viruses used in various nonhuman 
primate models of AIDS, the vaccine standard cannot be a 
single vaccine, but must be a standardized vaccine approach. 
For example, the vaccine approach could be deﬁ  ned by 
subcutaneous immunization of monkeys with a deﬁ  ned dose 
of a deﬁ  ned viral vector expressing codon-optimized gag and 
env genes at 24 and eight weeks before challenge. The degree 
of homology of the encoded Gag and Env proteins of the 
standard vaccine and the challenge virus should be the same 
as the homology between the antigens of the novel vaccine to 
be tested and those of the challenge virus. Thus, depending on 
the novel vaccines to be tested, different vaccine standards of 
the standardized vaccine approach are needed. 
Including deﬁ  ned vaccine standards in future efﬁ  cacy 
studies in nonhuman primate models would greatly facilitate 
preclinical evaluation of novel vaccine candidates and provide 
evidence-based criteria for their selection for clinical studies. 
Once an agreement on a standard vaccine approach has been 
reached, the approach could be implemented quickly, since 
efﬁ  cacy studies in nonhuman primates are well established. 
Given the urgent need for an HIV/AIDS vaccine, we cannot 
afford to ignore the only animal models that might well predict 
efﬁ  cacy in humans. Exploitation of the potential of carefully 
controlled comparative efﬁ  cacy studies in nonhuman primates 
should be considered by the Global HIV/AIDS Vaccine 
Enterprise. It remains to be discussed whether inclusion of a 
vaccine standard in clinical studies might also solve some of the 
standardization problems encountered.  
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